Base de dados : MEDLINE
Pesquisa : D02.033.100.291.617 [Categoria DeCS]
Referências encontradas : 12632 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1264 ir para página                         

  1 / 12632 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471102
[Au] Autor:Yoo SG; Cho MJ; Kim US; Baek SH
[Ad] Endereço:Department of Ophthalmology, Kim's Eye Hospital, Seoul, Korea.
[Ti] Título:Cycloplegic Refraction in Hyperopic Children: Effectiveness of a 0.5% Tropicamide and 0.5% Phenylephrine Addition to 1% Cyclopentolate Regimen.
[So] Source:Korean J Ophthalmol;31(3):249-256, 2017 Jun.
[Is] ISSN:2092-9382
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the effectiveness of a cycloplegic regimen using 0.5% tropicamide and 0.5% phenylephrine (Tropherine, Hanmi Pharm), in addition to 1% cyclopentolate, in hyperopic children. METHODS: The medical records of hyperopic patients below the age of 14 years who had undergone cycloplegic retinoscopy were retrospectively reviewed. Cycloplegic refractions were performed using one of two cycloplegic regimens. Regimen 1 was a Tropherine-added regimen comprising the administration of one drop of 1% cyclopentolate followed by two to three drops of Tropherine added at 15-minute intervals. Regimen 2 was a cyclopentolate-only regimen comprising the administration of three to four drops of 1% cyclopentolate at 15-minute intervals. The mean difference between noncycloplegic and cycloplegic refraction was compared between the two regimens. RESULTS: A total of 308 eyes of 308 hyperopic children were included. The mean difference (±standard deviation) in the spherical equivalent (SE) between cycloplegic and noncycloplegic refraction was significantly larger in regimen 2 than in regimen 1, with values of +1.70 ± 1.03 diopters (D) and +1.25 ± 0.89 D, respectively (p=0.001). The SE change after cycloplegia was significantly different between the two regimens only in patients aged 5 years or younger (p=0.001), particularly in those with high hyperopia with an SE ≥5 D (p=0.005) or fully accommodative esotropia (p=0.009). There was no significant difference between the two regimens in patients older than 5 years, regardless of the presence of high hyperopia or fully accommodative esotropia. CONCLUSIONS: The Tropherine-added regimen exerted a weaker cycloplegic effect than the cyclopentolate-only regimen, particularly in children under the age of 5 years with high hyperopia or fully accommodative esotropia. However, the difference in refraction between the two regimens was small. A Tropherine-added regimen can be effective in hyperopic children, with less associated discomfort than the instillation of cyclopentolate.
[Mh] Termos MeSH primário: Acomodação Ocular/efeitos dos fármacos
Ciclopentolato/administração & dosagem
Oftalmopatias Hereditárias/tratamento farmacológico
Hiperopia/tratamento farmacológico
Fenilefrina/administração & dosagem
Refração Ocular/efeitos dos fármacos
Tropicamida/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Quimioterapia Combinada
Oftalmopatias Hereditárias/fisiopatologia
Feminino
Seguimentos
Seres Humanos
Hiperopia/fisiopatologia
Lactente
Recém-Nascido
Masculino
Midriáticos/administração & dosagem
Soluções Oftálmicas/administração & dosagem
Estudos Retrospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mydriatics); 0 (Ophthalmic Solutions); 1WS297W6MV (Phenylephrine); I76F4SHP7J (Cyclopentolate); N0A3Z5XTC6 (Tropicamide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.3341/kjo.2016.0007


  2 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422100
[Au] Autor:Mikkelsen MLG; Ambrus R; Rasmussen R; Miles JE; Poulsen HH; Moltke FB; Eriksen T
[Ad] Endereço:Department of Veterinary Clinical Sciences, University of Copenhagen, 16 Dyrlægevej, 1870, Frederiksberg C, Denmark. mailo@sund.ku.dk.
[Ti] Título:The influence of norepinephrine and phenylephrine on cerebral perfusion and oxygenation during propofol-remifentanil and propofol-remifentanil-dexmedetomidine anaesthesia in piglets.
[So] Source:Acta Vet Scand;60(1):8, 2018 Feb 08.
[Is] ISSN:1751-0147
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vasopressors are frequently used to increase blood pressure in order to ensure sufficient cerebral perfusion and oxygenation (CPO) during hypotensive periods in anaesthetized patients. Efficacy depends both on the vasopressor and anaesthetic protocol used. Propofol-remifentanil total intravenous anaesthesia (TIVA) is common in human anaesthesia, and dexmedetomidine is increasingly used as adjuvant to facilitate better haemodynamic stability and analgesia. Little is known of its interaction with vasopressors and subsequent effects on CPO. This study investigates the CPO response to infusions of norepinephrine and phenylephrine in piglets during propofol-remifentanil and propofol-remifentanil-dexmedetomidine anaesthesia. Sixteen healthy female piglets (25-34 kg) were randomly allocated into a two-arm parallel group design with either normal blood pressure (NBP) or induced low blood pressure (LBP). Anaesthesia was induced with propofol without premedication and maintained with propofol-remifentanil TIVA, and finally supplemented with continuous infusion of dexmedetomidine. Norepinephrine and phenylephrine were infused in consecutive intervention periods before and after addition of dexmedetomidine. Cerebral perfusion measured by laser speckle contrast imaging was related to cerebral oxygenation as measured by an intracerebral Licox probe (partial pressure of oxygen) and transcranial near infrared spectroscopy technology (NIRS) (cerebral oxygen saturation). RESULTS: During propofol-remifentanil anaesthesia, increases in blood pressure by norepinephrine and phenylephrine did not change cerebral perfusion significantly, but cerebral partial pressure of oxygen (Licox) increased following vasopressors in both groups and increases following norepinephrine were significant (NBP: P = 0.04, LBP: P = 0.02). In contrast, cerebral oxygen saturation (NIRS) fell significantly in NBP following phenylephrine (P = 0.003), and following both norepinephrine (P = 0.02) and phenylephrine (P = 0.002) in LBP. Blood pressure increase by both norepinephrine and phenylephrine during propofol-remifentanil-dexmedetomidine anaesthesia was not followed by significant changes in cerebral perfusion. Licox measures increased significantly following both vasopressors in both groups, whereas the decreases in NIRS measures were only significant in the NBP group. CONCLUSIONS: Cerebral partial pressure of oxygen measured by Licox increased significantly in concert with the vasopressor induced increases in blood pressure in healthy piglets with both normal and low blood pressure. Cerebral oxygenation assessed by intracerebral Licox and transcranial NIRS showed opposing results to vasopressor infusions.
[Mh] Termos MeSH primário: Anestesia/veterinária
Circulação Sanguínea/efeitos dos fármacos
Córtex Cerebral/efeitos dos fármacos
[Mh] Termos MeSH secundário: Anestésicos Intravenosos/administração & dosagem
Animais
Córtex Cerebral/irrigação sanguínea
Córtex Cerebral/metabolismo
Dexmedetomidina/administração & dosagem
Hipnóticos e Sedativos/administração & dosagem
Norepinefrina/farmacologia
Oxigênio/metabolismo
Fenilefrina/farmacologia
Piperidinas/administração & dosagem
Propofol/administração & dosagem
Suínos
Vasoconstritores/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Intravenous); 0 (Hypnotics and Sedatives); 0 (Piperidines); 0 (Vasoconstrictor Agents); 1WS297W6MV (Phenylephrine); 67VB76HONO (Dexmedetomidine); P10582JYYK (remifentanil); S88TT14065 (Oxygen); X4W3ENH1CV (Norepinephrine); YI7VU623SF (Propofol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.1186/s13028-018-0362-z


  3 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29283546
[Au] Autor:Khan QS; Tucker P; Lokhande A
[Ti] Título:Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse?
[So] Source:J Okla State Med Assoc;109(11):515-7, 2016 11.
[Is] ISSN:0030-1876
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We present a case of priapism in a homeless patient with a psychiatric history of major depression, PTSD, polysubstance abuse (alcohol and cocaine) and past psychotropic medication use who was admitted to a local hospital for suicidal ideation. Priapism is a serious urological and a medical emergency which has often been associated with psychotropic medications (including the antidepressant trazodone), use of marijuana and alcohol, and other factors. This clinical case highlights the additive risks of medications and comorbid conditions in contributing to onset of priapism, emphasizing the importance of any pre-existing medical illness, diagnoses, and comorbid mental illnesses. Moreover, clinicians should consider potential side effects of all medications used and their drug interactions as they manage patients who develop this condition.
[Mh] Termos MeSH primário: Transtorno Depressivo Maior/tratamento farmacológico
Inibidores da Fosfodiesterase 5/efeitos adversos
Priapismo/induzido quimicamente
Hiperplasia Prostática/tratamento farmacológico
Inibidores da Captação de Serotonina/efeitos adversos
Citrato de Sildenafila/efeitos adversos
Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico
Trazodona/efeitos adversos
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Transtorno Depressivo Maior/complicações
Hepatite C/complicações
Seres Humanos
Masculino
Meia-Idade
Fenilefrina/uso terapêutico
Priapismo/tratamento farmacológico
Hiperplasia Prostática/complicações
Distúrbios do Início e da Manutenção do Sono/complicações
Transtornos Relacionados ao Uso de Substâncias/complicações
Sulfonamidas/uso terapêutico
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Phosphodiesterase 5 Inhibitors); 0 (Serotonin Uptake Inhibitors); 0 (Sulfonamides); 0 (Vasoconstrictor Agents); 1WS297W6MV (Phenylephrine); BW9B0ZE037 (Sildenafil Citrate); G3P28OML5I (tamsulosin); YBK48BXK30 (Trazodone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171229
[St] Status:MEDLINE


  4 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29233124
[Au] Autor:Lyu IJ; Park KA; Oh SY
[Ad] Endereço:Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
[Ti] Título:Increase in esodeviation under cycloplegia with 0.5% tropicamide and 0.5% phenylephrine mixed eye drops in patients with hyperopia and esotropia.
[So] Source:BMC Ophthalmol;17(1):247, 2017 Dec 12.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUD: To evaluate the manifestations of increased esodeviation under cycloplegia with 0.5% tropicamide and 0.5% phenylephrine in children with hyperopia and esotropia. METHODS: We reviewed the medical record of 34 children with hyperopia and esotropia who underwent a prism alternate cover test before and after instillation of mixed eye drops containing 0.5% tropicamide and 0.5% phenylephrine between November 2014 and October 2015. Increased angle of deviation was defined as 10 prism diopters (PD) or greater deviation after cycloplegia. The factors related to increased angle of deviation were evaluated using univariable and multivariable logistic regression analysis. RESULTS: The median age was 5.0 years (interquartile range, 3.75 to 5.0) and 12 patients (35.3%) were male. The median manifested refractive (MR) was +2.13 diopters (D) (+0.92 to +4.47) and cycloplegic refractive (CR) was +3.50 D (+1.72 to +5.66). The median difference between MR and CR was +0.88 D (+0.50 to +1.28). Thirteen patients (38.2%) showed increased esodeviation under cycloplegia and all had accommodative esotropia. A larger difference between MR and CR was the only significant factor affecting increased esodeviation in both univariable (OR = 4.72, P = 0.029) and multivariable (OR = 5.22, P = 0.047) analyses. CONCLUSION: Children with hyperopia and esotropia often showed an increased angle of deviation after instillation of 0.5% tropicamide and 0.5% phenylephrine. This phenomenon reminded the clinicians that cycloplegics can have a different effect on esodeviation and suggested that increased angle of esodeviation may help to reveal the latent deviation in some patients with hyperopia and esotropia.
[Mh] Termos MeSH primário: Esotropia/tratamento farmacológico
Hiperopia/tratamento farmacológico
Midriáticos/uso terapêutico
Fenilefrina/uso terapêutico
Refração Ocular/efeitos dos fármacos
Tropicamida/uso terapêutico
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Esotropia/fisiopatologia
Seres Humanos
Hiperopia/fisiopatologia
Modelos Logísticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mydriatics); 1WS297W6MV (Phenylephrine); N0A3Z5XTC6 (Tropicamide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-017-0644-7


  5 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Vassallo, Dalton Valentim
Texto completo
[PMID]:28987480
[Au] Autor:Rizzetti DA; Martín Á; Corrales P; Fernandez F; Simões MR; Peçanha FM; Vassallo DV; Miguel M; Wiggers GA
[Ad] Endereço:Cardiovascular Physiology Laboratory, Universidade Federal do Pampa, BR 472, Km 592, Uruguaiana, Rio Grande do Sul, Brazil. Electronic address: danize.rizzetti@gmail.com.
[Ti] Título:Egg white-derived peptides prevent cardiovascular disorders induced by mercury in rats: Role of angiotensin-converting enzyme (ACE) and NADPH oxidase.
[So] Source:Toxicol Lett;281:158-174, 2017 Nov 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The study aimed to investigate the effects of egg white hydrolysate (EWH) on vascular disorders induced by mercury (Hg). For this, male Wistar rats were treated for 60days: Untreated (saline, i.m.); Mercury (HgCl , i.m., 1st dose 4.6µg/kg, subsequent doses 0.07µg/kg/day); Hydrolysate (EWH, gavage, 1g/kg/day); Hydrolysate-Mercury. Systolic (SBP) and diastolic (DBP) blood pressure measurement and vascular reactivity experiments in aorta were performed. We analyzed endothelial dependent and independent vasodilator responses and vasoconstrictor response to phenylephrine (Phe) in absence and presence of endothelium, a NOS inhibitor, a NADPH oxidase inhibitor, the superoxide dismutase, a non-selective COX inhibitor, a selective COX-2 inhibitor, an AT-1 receptors blocker. In situ superoxide anion production, SOD-1, NOX-4, p22phox, COX-2 and AT-1 mRNA levels and NOX-1 protein expression were performed in aorta while the determination of angiotensin converting enzyme (ACE) activity was measured in plasma. As results, EWH prevented the increase in SBP and Phe responses and the endothelial dysfunction elicited by Hg, which was related to decreased ACE activity and NOX activation by EWH and, subsequently, alleviated ROS production and improved NO bioavailability in aorta. In conclusion, EWH could be considered as alternative or complementary treatment tools for Hg-induced cardiovascular damage.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/tratamento farmacológico
Clara de Ovo/química
Mercúrio/toxicidade
NADPH Oxidases/sangue
Peptídeos/farmacologia
Peptidil Dipeptidase A/sangue
[Mh] Termos MeSH secundário: Animais
Aorta/efeitos dos fármacos
Aorta/metabolismo
Pressão Sanguínea/efeitos dos fármacos
Doenças Cardiovasculares/induzido quimicamente
Relação Dose-Resposta a Droga
Endotélio Vascular/efeitos dos fármacos
Masculino
NADPH Oxidases/antagonistas & inibidores
Estresse Oxidativo/efeitos dos fármacos
Fenilefrina/farmacologia
Ratos
Ratos Wistar
Vasoconstritores/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Peptides); 0 (Vasoconstrictor Agents); 1WS297W6MV (Phenylephrine); EC 1.6.3.- (NADPH Oxidases); EC 3.4.15.1 (Peptidyl-Dipeptidase A); FXS1BY2PGL (Mercury)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171009
[St] Status:MEDLINE


  6 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28941803
[Au] Autor:Xue R; Jiang J; Dong B; Tan W; Sun Y; Zhao J; Chen Y; Dong Y; Liu C
[Ad] Endereço:Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Key Laboratory on Assisted Circulation, Ministry of Health, Guangzhou, China.
[Ti] Título:DJ-1 activates autophagy in the repression of cardiac hypertrophy.
[So] Source:Arch Biochem Biophys;633:124-132, 2017 Nov 01.
[Is] ISSN:1096-0384
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cardiac hypertrophy is the risk factor of heart failure when the heart is confronted with pressure overload or neurohumoral stimuli. Autophagy, a conserved degradative pathway, is one of the important mechanisms involved in the regulation of cardiac hypertrophy. DJ-1 is a traditional anti-oxidative protein and emerging evidence suggested that DJ-1 might modulate autophagy. However, the regulation of autophagy by DJ-1 in the process of cardiac hypertrophy remains unknown. In our study, we firstly discovered that the expression of DJ-1declined in the process of pressure overload cardiac hypertrophy, and its alteration was parallel with the impairment of autophagy. Furthermore, we proved that DJ-1 knockout mice exhibited a more hypertrophied phenotype than wildtype mice in cardiac hypertrophy which indicated that DJ-1 is responsible for the repression of cardiac hypertrophy. Furthermore, DJ-1 knockout significantly exacerbated pulmonary edema due to cardiac hypertrophy. In the process of cardiac hypertrophy, DJ-1 knockout significantly impaired autophagy activation and enhanced mTORC1 and mTORC2 phosphorylation were found. Similarly, our in vitro study proved that DJ-1 overexpression ameliorated phenylephrine (PE)-induced cardiac hypertrophy and promoted autophagy activation. Taken together, DJ-1 might repress both pressure overload and PE-induced cardiac hypertrophy via the activation of autophagy.
[Mh] Termos MeSH primário: Autofagia/genética
Cardiomegalia/genética
Pulmão/metabolismo
Miocárdio/metabolismo
Proteína Desglicase DJ-1/genética
Edema Pulmonar/genética
[Mh] Termos MeSH secundário: Animais
Autofagia/efeitos dos fármacos
Cardiomegalia/induzido quimicamente
Cardiomegalia/metabolismo
Cardiomegalia/patologia
Regulação da Expressão Gênica
Pulmão/patologia
Alvo Mecanístico do Complexo 1 de Rapamicina
Alvo Mecanístico do Complexo 2 de Rapamicina
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Complexos Multiproteicos/genética
Complexos Multiproteicos/metabolismo
Miocárdio/patologia
Miócitos Cardíacos/efeitos dos fármacos
Miócitos Cardíacos/metabolismo
Miócitos Cardíacos/patologia
Fenilefrina/efeitos adversos
Fosforilação
Cultura Primária de Células
Proteína Desglicase DJ-1/deficiência
Edema Pulmonar/induzido quimicamente
Edema Pulmonar/metabolismo
Edema Pulmonar/patologia
Ratos Sprague-Dawley
Índice de Gravidade de Doença
Serina-Treonina Quinases TOR/genética
Serina-Treonina Quinases TOR/metabolismo
Vasoconstritores/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Multiprotein Complexes); 0 (Vasoconstrictor Agents); 1WS297W6MV (Phenylephrine); EC 2.7.1.1 (TOR Serine-Threonine Kinases); EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1); EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2); EC 3.1.2.- (PARK7 protein, mouse); EC 3.1.2.- (Protein Deglycase DJ-1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170925
[St] Status:MEDLINE


  7 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28860353
[Au] Autor:Zheng C; Zhong M; Qi Z; Shen F; Zhao Q; Wu L; Huang Y; Tsang SY; Yao X
[Ad] Endereço:Department of Physiology, Anhui Medical University, Hefei, China (M.Z., F.S.); School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, Yunnan, China (C.Z.); and School of Biomedical Sciences and Li Ka Shing Institute of He
[Ti] Título:Histone Deacetylase Inhibitors Relax Mouse Aorta Partly through Their Inhibitory Action on L-Type Ca Channels.
[So] Source:J Pharmacol Exp Ther;363(2):211-220, 2017 Nov.
[Is] ISSN:1521-0103
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Histone deacetylase (HDAC) inhibitors modulate acetylation/deacetylation of histone and nonhistone proteins. They have been widely used for cancer treatment. However, there have been only a few studies investigating the effect of HDAC inhibitors on vascular tone regulation, most of which employed chronic treatment with HDAC inhibitors. In the present study, we found that two hydroxamate-based pan-HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA), could partially but acutely relax high extracellular K -contracted mouse aortas. SAHA and TSA also attenuated the high extracellular K -induced cytosolic Ca rise and inhibited L-type Ca channel current in whole-cell patch-clamp. These data demonstrate that SAHA could inhibit L-type Ca channels to cause vascular relaxation. In addition, SAHA and TSA dose dependently relaxed the arteries precontracted with phenylephrine. The relaxant effect of SAHA and TSA was greater in phenylephrine-precontracted arteries than in high K -contracted arteries. Although part of the relaxant effect of SAHA and TSA on phenylephrine-precontracted arteries was related to L-type Ca channels, both agents could also induce relaxation via a mechanism independent of L-type Ca channels. Taken together, HDAC inhibitors SAHA and TSA can acutely relax blood vessels via their inhibitory action on L-type Ca channels and via another L-type Ca channel-independent mechanism.
[Mh] Termos MeSH primário: Aorta/efeitos dos fármacos
Aorta/fisiologia
Canais de Cálcio Tipo L/metabolismo
Inibidores de Histona Desacetilases/farmacologia
Ácidos Hidroxâmicos/farmacologia
Vasodilatação/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Aorta/metabolismo
Transporte Biológico/efeitos dos fármacos
Cálcio/metabolismo
Citosol/efeitos dos fármacos
Citosol/metabolismo
Fenômenos Eletrofisiológicos/efeitos dos fármacos
Espaço Extracelular/efeitos dos fármacos
Espaço Extracelular/metabolismo
Masculino
Camundongos
Músculo Liso Vascular/citologia
Músculo Liso Vascular/metabolismo
Fenilefrina/farmacologia
Potássio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcium Channels, L-Type); 0 (Histone Deacetylase Inhibitors); 0 (Hydroxamic Acids); 1WS297W6MV (Phenylephrine); 3X2S926L3Z (trichostatin A); 58IFB293JI (vorinostat); RWP5GA015D (Potassium); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.117.242685


  8 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28855109
[Au] Autor:Li H; Kim HW; Shin SE; Seo MS; An JR; Ha KS; Han ET; Hong SH; Firth AL; Choi IW; Han IY; Lee DS; Yim MJ; Park WS
[Ad] Endereço:Department of Physiology, Kangwon National University School of Medicine, Chuncheon 24341, South Korea.
[Ti] Título:The vasorelaxant effect of mitiglinide via activation of voltage-dependent K channels and SERCA pump in aortic smooth muscle.
[So] Source:Life Sci;188:1-9, 2017 Nov 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: The vasorelaxant effects of the anti-diabetic drug, mitiglinide in phenylephrine (Phe)-pre-contracted aortic rings were examined. MATERIALS AND METHODS: Arterial tone measurement was performed in aortic smooth muscle cells. KEY FINDINGS: Mitiglinide dose-dependently induced vasorelaxation. Application of the large-conductance Ca -activated K (BK ) channel blocker paxilline, inwardly rectifying K (Kir) channel blocker Ba , and ATP-sensitive K (K ) channel blocker glibenclamide did not affect the vasorelaxant effect of mitiglinide. However, application of the voltage-dependent K (Kv) channel blocker 4-AP, effectively inhibited mitiglinide-induced vasorelaxation. Although pretreatment with the Ca channel blocker nifedipine did not alter the mitiglinide-induced vasorelaxation, pretreatment with the sarcoplasmic/endoplasmic reticulum Ca -ATPase (SERCA) pump inhibitor thapsigargin and cyclopiazonic acid reduced the vasorelaxant effect of mitiglinide. In addition, the vasorelaxant effect of mitiglinide was not affected by the inhibitors of adenylyl cyclase, protein kinase A, guanylyl cyclase, or protein kinase G. Elimination of the endothelium and inhibition of endothelium-dependent vasorelaxant mechanisms also did not change the vasorelaxant effect of mitiglinide. SIGNIFICANCE: We proposed that mitiglinide induces vasorelaxation via activation of Kv channels and SERCA pump. However, the vasorelaxant effects of mitiglinide did not involve other K channels, Ca channels, PKA/PKG signaling pathways, or the endothelium.
[Mh] Termos MeSH primário: Aorta Torácica/fisiologia
Isoindóis/farmacologia
Músculo Liso/fisiologia
Canais de Potássio de Abertura Dependente da Tensão da Membrana/agonistas
ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/fisiologia
Vasodilatadores/farmacologia
[Mh] Termos MeSH secundário: 4-Aminopiridina/farmacologia
Adenina/análogos & derivados
Adenina/farmacologia
Animais
Aorta Torácica/efeitos dos fármacos
Bário/farmacologia
Carbazóis/farmacologia
Relação Dose-Resposta a Droga
Interações Medicamentosas
Endotélio Vascular/efeitos dos fármacos
Glibureto/farmacologia
Indóis/farmacologia
Isoindóis/antagonistas & inibidores
Masculino
Músculo Liso/efeitos dos fármacos
Nifedipino/farmacologia
Oxidiazóis/farmacologia
Fenilefrina/farmacologia
Pirróis/farmacologia
Quinoxalinas/farmacologia
Coelhos
ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/antagonistas & inibidores
Transdução de Sinais/efeitos dos fármacos
Tapsigargina/farmacologia
Vasodilatadores/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one); 0 (Carbazoles); 0 (Indoles); 0 (Isoindoles); 0 (Oxadiazoles); 0 (Potassium Channels, Voltage-Gated); 0 (Pyrroles); 0 (Quinoxalines); 0 (Vasodilator Agents); 126643-37-6 (KT 5823); 17318-31-9 (9-(tetrahydro-2-furyl)-adenine); 1WS297W6MV (Phenylephrine); 24GP945V5T (Barium); 3T9U9Z96L7 (paxilline); 58HV29I28S (KT 5720); 67526-95-8 (Thapsigargin); BH3B64OKL9 (4-Aminopyridine); D86I0XLB13 (mitiglinide); EC 3.6.3.8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases); I9ZF7L6G2L (Nifedipine); JAC85A2161 (Adenine); SX6K58TVWC (Glyburide); X9TLY4580Z (cyclopiazonic acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE


  9 / 12632 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28799895
[Au] Autor:Medeiros RF; Gaique TG; Bento-Bernardes T; Kindlovits R; Gomes TMB; Motta NAV; Brito FC; Fernandes-Santos C; Oliveira KJ; Nóbrega ACL
[Ad] Endereço:1Department of Physiology and Pharmacology,Fluminense Federal University,24210-130 Niterói,Rio de Janeiro,Brazil.
[Ti] Título:Arginine and aerobic training prevent endothelial and metabolic alterations in rats at high risk for the development of the metabolic syndrome.
[So] Source:Br J Nutr;118(1):1-10, 2017 Jul.
[Is] ISSN:1475-2662
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Endothelial function is a key mechanism in the development of CVD. Arginine and exercise are important non-pharmacological strategies for mitigating the impact of metabolic changes in the metabolic syndrome, but the effect of their combined administration is unknown. Thus, the aim of this study was to investigate the isolated and combined effects of aerobic training and arginine supplementation on metabolic variables and vascular reactivity in rats at high risk for developing the metabolic syndrome. Wistar rats were divided into two groups: control and fructose (F - water with 10 % fructose). After 2 weeks, the F group was divided into four groups: F, fructose+arginine (FA, 880 mg/kg per d of l-arginine), fructose+training (FT) and fructose+arginine+training (FTA); treatments lasted for 8 weeks, and no difference was observed in body mass gain. Arginine did not improve the body protein content, and both the FA and FT groups show a reversal of the increase in adipose tissue. Insulin increase was prevented by training and arginine, without additive effect, and the increase in serum TAG was prevented only by training. The F group showed impaired endothelium-dependent vasodilation and hyperreactivity to phenylephrine, but arginine and training were capable of preventing these effects, even separately. Higher nitric oxide level was observed in the FA and FT groups, and no potentiating effect was detected. Thus, only training was able to prevent the increase in TAG and improve the protein mass, and training and arginine exert similar effects on fat content, insulin and endothelial function, but these effects are not additive.
[Mh] Termos MeSH primário: Arginina/farmacologia
Endotélio Vascular/fisiologia
Síndrome Metabólica/prevenção & controle
Condicionamento Físico Animal/fisiologia
[Mh] Termos MeSH secundário: Tecido Adiposo/metabolismo
Animais
Composição Corporal/efeitos dos fármacos
Suplementos Nutricionais
Endotélio Vascular/efeitos dos fármacos
Frutose
Insulina/sangue
Masculino
Síndrome Metabólica/metabolismo
Óxido Nítrico/sangue
Fenilefrina/farmacologia
Proteínas/metabolismo
Ratos Wistar
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 0 (Proteins); 0 (Triglycerides); 1WS297W6MV (Phenylephrine); 30237-26-4 (Fructose); 31C4KY9ESH (Nitric Oxide); 94ZLA3W45F (Arginine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE
[do] DOI:10.1017/S0007114517001702


  10 / 12632 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28774515
[Au] Autor:Liu JC; Green W; Van Stavern GP; Culican SM
[Ad] Endereço:Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO; Indiana University School of Medicine Transitional Residency Program, Indianapolis, IN.. Electronic address: jameschangliu@gmail.com.
[Ti] Título:Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation.
[So] Source:Can J Ophthalmol;52(4):349-354, 2017 Aug.
[Is] ISSN:1715-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate whether the addition of phenylephrine to tropicamide produces any clinically significant change in pupil size during diagnostic eye examination. METHODS: Twenty healthy adults at the Washington University School of Medicine Eye Clinic were enrolled in this prospective, nonrandomized, crossover trial. Each had 3 dilating eye drop regimens administered to the left eye on separate days. Tropicamide (T) + proparacaine (PP) + phenylephrine (PE) (T+PP+PE) was considered the standard therapy, to which tropicamide alone (T alone) and tropicamide + proparacaine (T+PP) were compared against. Main outcome measures were postdilation pupil size and proportion of pupils able to achieve adequate clinical pupil dilation of >7 mm. Comparisons were made using Wilcoxon signed-ranked tests and McNemar's test. RESULTS: Mean postdilation pupil size was 7.94 ± 0.78 mm, 7.64 ± 0.78 mm, and 7.48 ± 0.77 mm for T+PP+PE, T+PP, and T alone, respectively. T+PP+PE was statistically superior to T+PP (p = 0.004) and T alone (p < 0.001) with respect to postdilation pupil size. The proportion of pupils able to achieve adequate pupil dilation of >7 mm was 90%, 80%, and 70% for T+PP+PE, T+PP, and T alone, respectively. No statistical difference was observed in each regimen's ability to achieve adequate pupil dilation of >7 mm (T+PP+PE and T+PP: p = 0.47; T+PP+PE and T alone: p = 0.13). CONCLUSION: The addition of phenylephrine eye drops to tropicamide produced larger pupil dilation, but the magnitude of benefit was marginal and clinically insignificant in this young, healthy cohort. A single-dilating-agent regimen using tropicamide could be considered in routine clinical practice.
[Mh] Termos MeSH primário: Uso de Medicamentos
Oftalmopatias/diagnóstico
Fenilefrina/administração & dosagem
Pupila/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Estudos Cross-Over
Relação Dose-Resposta a Droga
Feminino
Seguimentos
Voluntários Saudáveis
Seres Humanos
Masculino
Midriáticos/administração & dosagem
Soluções Oftálmicas
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mydriatics); 0 (Ophthalmic Solutions); 1WS297W6MV (Phenylephrine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170805
[St] Status:MEDLINE



página 1 de 1264 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde